



- (51) **International Patent Classification:**  
*C12R 1/19* (2006.01) *C12N 15/70* (2006.01)
- (21) **International Application Number:**  
PCT/US2017/024857
- (22) **International Filing Date:**  
29 March 2017 (29.03.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
62/3 14,924 29 March 2016 (29.03.2016) US
- (71) **Applicant:** GELTOR, INC. [US/US]; 1933 Davis Street, Suite 312, San Leandro, CA 94577 (US).
- (72) **Inventor:** OUZOUNOV, Nikolay; 1333 Pearl Street, Apt. H, Alameda, CA 94501 (US).
- (74) **Agent:** SHU, Young J.; Weaver Austin Villeneuve & Sampson LLP, P.O. Box 70250, Oakland, CA 946 12-0250 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**


- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H))*

**Published:**

- *with international search report (Art. 21(3))*

- (54) **Title:** EXPRESSION OF PROTEINS IN GRAM-NEGATIVE BACTERIA WHEREIN THE RATIO OF PERIPLASMIC VOLUME TO CYTOPLASMIC VOLUME IS BETWEEN 0.5: 1 AND 10: 1

Fig. 1



- (57) **Abstract:** Provided are modified Gram-negative bacteria having an increased periplasmic volume. Also provided are methods of expressing exogenous genes in the bacteria and targeting protein production to the periplasmic space.



**EXPRESSION OF PROTEINS IN GRAM-NEGATIVE BACTERIA WHEREIN THE RATIO OF PERIPLASMIC VOLUME TO CYTOPLASMIC VOLUME IS BETWEEN 0.5:1 AND 10:1**

**BACKGROUND**

**Field**

5           The invention relates to modified Gram-negative bacteria having an increased periplasmic volume, and methods of expressing exogenous genes therein. The bacteria are useful for targeting recombinant protein production to the periplasmic space.

**Description of the Related Art**

10           In spite of longstanding efforts to optimize prokaryotic expression systems, a number of obstacles still remain to obtaining sufficient yields of functionally active gene products, including the formation of inclusion bodies, incorrect folding of the expressed protein, toxicity for the producer cells and degradation by proteases. A variety of alternative expression systems are being developed and evaluated to produce recombinant proteins more effectively.

15           *Escherichia coli* is the most commonly used host for the production of recombinant proteins. In order to obtain the target exogenous proteins expressed intracellularly in recombinant *E. coli*, however, cell disruption is necessary, which can increase of pyrogen level (mainly from the cell membrane composition), increase sample impurities and decrease protein activities. Particularly, the formation of inclusion bodies often occurs when the target protein is intracellularly overexpressed. To overcome these  
20           problems, extracellular secretion of exogenous proteins in recombinant *E. coli* is becoming an increasingly popular choice. In large-scale industrial production of exogenous proteins, the extracellular excretion of target proteins can remove the cell disruption step, offer a better environment for protein folding and reduce the risk of intracellular enzyme degradation (Mergulhao *et al*, 2005, *Biotechnol Adv* 23: 177-202). Additionally, the extracellular secretion of target proteins can improve the recombinant protein  
25           yield because the target protein accumulation is not limited in periplasmic or intracellular space (Makrides, 1996, *Microbiol Rev* 60: 512-538; Fu *et al*, 2005, *Biotechnol Prog* 21: 1429-1435).

          The primary challenge with the extracellular secretion of recombinant proteins are the difficulties inherent in protein translocation across both the cell membrane and the outer membrane *oiE. coli* cells (Koebnik *et al*, 2000, *Mol Microbiol* 37: 239-253; Choi and Lee, 2004, *Appl Microbiol Biotechnol* 64:  
30           625-635). While periplasmic expression of recombinant proteins can often be achieved with the help of a signal peptide, the available methods to overcome the outer membrane barrier for extracellular production of recombinant proteins are much more limited. In order to solve this problem, various genetic attempts have been made to facilitate the extracellular secretion of recombinant proteins in *E. coli*, including manipulation of transport pathways (Sugamata and Shiba, 2005, *Appl Environ Microbiol* 71: 656-662),

optimization of codon and signal sequence (Takemori *et al.*, 2012, *Protein Expr Purif* 81: 145-150), fusion expression of carrier protein which can be normally secreted extracellularly (Fernandez *et al.*, 2000, *Appl Environ Microbiol* 66: 5024-5029; Choi and Lee, 2004) and fusion expression of outer membrane protein F (Jeong and Lee, 2002, *Appl Environ Microbiol* 68: 4979-4985), YebF (Zhang *et al.*, 5 2006, *Nat Biotechnol* 24: 100-104) or osmotically inducible protein Y (Qian *et al.*, 2008, *Biotechnol Bioeng* 101: 587-601). In addition, the coexpression of lysis-promoting proteins such as bacteriocin release protein (BRP) (van der Wal *et al.*, 1995, *Appl Microbiol Biotechnol* 44: 459-465) or colicin E1 lysis protein (Kil) (Robbens *et al.*, 1995, *Protein Expr Purif* 6: 481-486), as well as the use of wall-less strains (the so-called L-forms) (Gumpert and Hoischen, 1998, *Current Opinion in Biotechnology*, 9: 506-10 509) have also been reported.

Meanwhile, many fermentation techniques, including changes of culture medium compositions (Fu, 2010, *Appl Microbiol Biotechnol* 88: 75-86), temperature (Rinas and Hoffmann, 2004, *Biotechnol Prog*, 20: 679-687), aeration and calcium ion (Shokri *et al.*, 2003, *Appl Microbiol Biotechnol* 60: 654-664), osmotic pressure and induction conditions (Orr *et al.*, 2012, *J Biotechnol* 161, 19-26), as well as the 15 addition of supplements such as glycine (Yang *et al.*, 1998, *Appl Environ Microbiol* 64: 2869-2874) and Triton X-100 (Fu *et al.*, 2005, *Biotechnol Prog* 21: 1429-1435; Fu, 2010), have been explored to achieve the extracellular production of recombinant proteins in *E. coli*. The main disadvantage of the fermentation control for the extracellular production of target proteins is that the fermentation conditions vary greatly with different target proteins.

20 Leaky strains (including the *E. coli* Sec pathway) offer an alternative means for transporting periplasmic-directed recombinant proteins into media that overcomes the uncertainty of the fermentation conditions. Leaky strains can be constructed by knocking out genes related to the biosynthesis of cell wall and membrane, especially of the outer membrane genes such as *lpp* encoding Braun's lipoprotein (Shin and Chen, 2008, *Biotechnol Bioeng* 101: 1288-1296) of *E. coli*. More recently, Chen *et al.* (*Microbial 25 Biotechnology*, 2014, 7, 360-370) constructed several leaky strains of *E. coli* JM109 (DE3), including *mrcA*, *mrcB*, *pal* and *lpp* (single-gene knock-out), and *lpp mrcB*, *mrcA lpp*, *lpp pal*, *mrcA pal* and *mrcB pal* (double-gene knock-out), by an inframe deletion method to improve the extracellular secretory levels of their target proteins. Extracellular yields of recombinant protein Trx-hPTH (human parathyroid hormone 1-84 coupled with thioredoxin as a fusion partner) from the mutants with double deletion were 30 significantly higher than those from the mutants with single deletion under the same conditions. In addition, mutants with inframe single/double deletion of genes, *mrcB* and *lpp*, could not cause the efficient leakage of the target protein due to protein expression in the cytoplasm rather than the periplasm. Accordingly, while the main advantage of leaky strains is that no additives are needed to induce extracellular protein production, the main disadvantage is that their secretory selectivity is not high,

suggesting that these genes affect the structure of the outer membrane but do not participate in the active transport of target protein(s).

L-form bacteria, or L-forms, are bacterial strains derived from parent species (N-forms) that are able to grow as cell wall-deficient (spheroplast type) or as cell wall-less (protoplast type) cells. *See*,  
5 Madoff S (Ed): The Bacterial L-Forms. New York: Marcel Dekker Inc., 1986; Mattmann LH (Ed): Cell Wall Deficient Forms. Boca Raton: CRC Press; 1993; and Gumpert J, Taubeneck U : Characteristic properties and biological significance of stable protoplast type L-forms. In Protoplasts, Lecture Proceedings of the 6<sup>th</sup> International Protoplast Symposium: Basel. Experientia 1983, 46(suppl):227-241.

Protoplast type L-forms have been cultivated in the cell wall-less state and represent genetically  
10 stable mutants showing extreme pleiotropic changes, including the inability to form cell walls, capsules, flagella, pili, spores and mesosomes, altered colony and cell morphology, qualitative and quantitative changes in the lipid and protein components of the cytoplasmic membrane, the absence of extracellular proteolytic activities, resistance against bacteriophages and the incapability to propagate outside laboratory conditions. *See*, Gumpert and Taubeneck (*supra*); and Hoischen *et al.*, Lipid and fatty acid  
15 composition of cytoplasmic membranes from *Streptomyces hygroscopicus* and its stable protoplast type L-form. J Bacteriol 1997, 179:3430-3436.

Gumpert and Hoischen (Current Opinion in Biotechnology, 1998, 9:506-509) describe expression systems in which cell wall-less L-form strains of *Proteus mirabilis*, *Escherichia coli*, *Bacillus subtilis*, and *Streptomyces hygroscopicus* were used to synthesize various recombinant proteins in considerable  
20 amounts as soluble, functionally active products. The recombinant proteins were secreted by the L-form cells into the surrounding growth medium by an active translocation process that required appropriate signal peptides. Among the proteins synthesized were correctly processed antibodies and miniantibodies, indicating that the appropriate post-translational modifications (correct folding, formation of disulfide bonds, and dimerization) had occurred. The authors noted that because the L-form strains lacked a  
25 periplasmic compartment this is not a necessary prerequisite for post-translational processing and that the cytoplasmic membrane of the L-form cells plays a role in these modification processes. The L-form cells were more sensitive to environmental influences than widely-used *E. coli* expression systems and they needed more careful handling, in particular, control of the inoculum, the avoidance of contacts with membrane-active surfactants and other aggressive substances, and complex growth media. The authors  
30 concluded that the most important advantage of their L-form expression system was the removal of the synthesized protein by active translocation through the cytoplasmic membrane and secretion into the surrounding growth medium, and that it was probably not useful for large scale fermentations.

Accordingly, there is clearly still a need for improved methods for the fermentative preparation of proteins. The recombinant bacteria, cell culture media, and processes described herein help meet these and other needs.

5

### BRIEF SUMMARY

The present invention solves the foregoing problems in the prior art by providing compositions and methods for the enhanced periplasmic production of recombinant proteins. In particular, modified bacterial cells are provided exhibiting a novel physiological state which inhibits cell division and promotes the growth of the periplasmic space in comparison to the cytoplasmic space. As demonstrated for the first time herein, recombinant protein production in these cells is dramatically increased compared with that in non-switched cells. Structurally, the cells comprise both inner and outer membranes but lack a functional peptidoglycan cell wall, while the cell shape is spherical and increases in volume over time. Notably, while the periplasmic space normally comprises only 10-20% of the total cell volume, the periplasmic compartment of the switched state described herein can comprise more than 20%, 30%, 40% or 50% and up to 60%, 70%, 80% or 90% of the total cell volume. In some cases, this increased periplasmic space provides for dramatically increased expression of recombinant proteins into the periplasmic space.

In one aspect, modified bacterial cells are provided exhibiting this switched phenotype, where the periplasmic space in the subject bacterial cells comprises at least about 20% or 25% of the total cell volume, more preferably at least about 30%, 35%, 40%, or 45% of the total cell volume, still more preferably at least about 50%, 55%, 60%, 65%, or 70% of the total cell volume, and most preferably at least about 75%, 80%, 85% or 90% of the total cell volume.

Preferably, the modified bacterial cells of the subject invention are derived from Gram-negative bacteria, e.g. selected from: *gammaproteobacteria* and *alphaproteobacteria*. In particularly preferred embodiments, the bacterium is selected from: *Escherichia coli*, *Vibrio natriegens*, *Pseudomonas fluorescens*, *Caulobacter crescentus*, *Agrobacterium tumefaciens*, and *Brevundimonas diminuta*. In specific embodiments, the bacterium is *Escherichia coli*, e.g. strain BL21, BL21(DE3), or K12.

In some embodiments, the modified bacterial cells according to the present invention have a ratio of periplasmic volume to cytoplasmic volume between about 0.5: 1 and about 10: 1, between about 0.5: 1 and about 5:1, between about 0.5: 1 and about 1:1, between about 1:1 and about 10: 1, between about 1:1 and about 5:1, or between about 5:1 and about 10: 1.

In some embodiments, a modified bacterial cell of the present invention is a coccus having a longest dimension of about 2  $\mu\text{m}$  to about 16  $\mu\text{m}$ , more preferably about 4  $\mu\text{m}$  to about 16  $\mu\text{m}$ , still more

preferably about 8  $\mu\text{m}$  to about 16  $\mu\text{m}$ , or about 2  $\mu\text{m}$  to about 8  $\mu\text{m}$ , or about 4  $\mu\text{m}$  to about 8  $\mu\text{m}$ , or about 2  $\mu\text{m}$  to about 4  $\mu\text{m}$ .

Preferably, the modified bacterial cells of the subject invention further comprise an exogenous gene encoding a protein of interest. Proteins of interest can be therapeutic, *e.g.*, antibodies, hormones, growth factors, vaccines, and any other functional and/or structural proteins and enzymes of medical interest, as well as non-therapeutic, *e.g.*, collagen and derivatives thereof, albumin, ovalbumin, rennet, fibrin, casein (including  $\alpha\text{S1}$ ,  $\alpha\text{S2}$ ,  $\beta$ ,  $\kappa$ ), elastin, keratin, myosin, fibronectin, laminin, nidogen-1, vitronectin, silk fibroins, prolyl hydroxylases, lysyl hydroxylases, glycosyltransferases, heme proteins, and any other structural or non-structural proteins or enzymes of commercial and/or academic interest.

Proteins of interest herein may exclude fluorescent proteins. In certain embodiments, the protein is other than mCherry or green fluorescent protein.

In one embodiment, the exogenous gene is integrated into the host bacterial cell genome. In another embodiment, the bacterial cell comprises an expression vector comprising the exogenous gene. In some embodiments, the expression vector is free of a marker encoding for resistance to an inhibitor of bacterial cell peptidoglycan biogenesis. In an exemplary embodiment, the expression vector comprises a pET plasmid. In a particular embodiment, the expression vector comprises plasmid pET28a.

In one embodiment, expression of the exogenous gene is constitutive. In another embodiment, expression of the exogenous gene is inducible. In some embodiments, expression of the exogenous gene is inducible by an inducer selected from, *e.g.* isopropyl- $\beta$ -D-thiogalactopyranoside, lactose, arabinose, maltose, tetracycline, anhydrotetracycline, vancomycin, xylose, copper, zinc, and the like.

In one embodiment, the modified bacterial cells further comprise a nucleic acid sequence encoding a signal peptide operably linked to the exogenous gene, wherein the signal peptide directs cotranslational export of the protein from the cytoplasm to the periplasm. In some embodiments, the signal peptide is derived from a protein component of the Sec and Tat secretion pathways. In particular embodiments, the signal peptide is derived from DsbA, *pelB*, *OmpA*, *TolB*, *MalE*, *lpp*, *TorA*, or *HylA*. For example, the signal peptide can be an N-terminal portion of DsbA, *pelB*, *OmpA*, *TolB*, *MalE*, *lpp*, *TorA*, or *HylA* that directs cotranslational export of the protein from the cytoplasm to the periplasm. In some cases, the signal peptide can contain at least 10%, 25%, 50%, 75%, 95%, 99%, or all of a peptide selected from DsbA, *pelB*, *OmpA*, *TolB*, *MalE*, *lpp*, *TorA*, or *HylA*.

In some embodiments, the modified bacterial cell comprises a coccus form of an ampicillin sensitive (*amp<sup>S</sup>*) and/or fosfomycin-sensitive bacillus strain, wherein the coccus form and the bacillus strain are genetically identical.

In another aspect, cell cultures are provided comprising bacterial cells having an enlarged periplasmic space in a culture medium comprising a magnesium salt, wherein the concentration of

magnesium ions in the medium is at least about 4, 5 or 6 mM. In further embodiments, the concentration of magnesium ions in the medium is at least about 7, 8, 9 or 10 mM. In some embodiments, the concentration of magnesium ions in the medium is between about 6 mM and about 20 mM. In some embodiments, the magnesium salt is selected from: magnesium sulfate and magnesium chloride.

5 Preferably, the cell culture of the subject invention further comprises an osmotic stabilizer, including, *e.g.* sugars (*e.g.*, arabinose, glucose, sucrose, glycerol, sorbitol, mannitol, fructose, galactose, saccharose, maltotrioseerythritol, ribitol, pentaerythritol, arabitol, galactitol, xylitol, iditol, maltotriose, and the like), betaines (*e.g.*, trimethylglycine), proline, one or more salts such as an ammonium, potassium, or sodium salt (*e.g.*, sodium chloride), one or more polymers (*e.g.*, polyethylene glycol, polyethylene glycol monomethylether, polysucrose, polyvinylpyrrolidone, polypropylene glycol), or a  
10 combination thereof. In some cases, the concentration of the osmotic stabilizer(s) in the medium is at least about 4%, 5%, 6%, or 7% (w/v). In further embodiments, the concentration of osmotic stabilizer is at least about 8%, 9%, or 10% (w/v). In some embodiments, the concentration of the osmotic stabilizer in the medium is between about 5% to about 20% (w/v).

15 In some embodiments, the cell culture may further comprise ammonium chloride, ammonium sulfate, calcium chloride, amino acids, iron(II) sulfate, magnesium sulfate, peptone, potassium phosphate, sodium chloride, sodium phosphate, and yeast extract. In some embodiments, the cell culture is free of animal-derived components. In some embodiments, the cell culture comprises, consists essentially of, or is in, a defined medium.

20 In some embodiments, the cell culture comprises from about  $1 \times 10^8$  bacterial cells per mL of culture volume to about  $1 \times 10^{10}$  bacterial cells per mL in a volume of at least about 1 L (*e.g.*, from about 1 L to about 500,000 L, from about 1 L to about 10,000 L, from about 1 L to about 1,000 L, from about about 1 L to about 500 L, or from about 1 L to about 250 L). In some embodiments, the cell culture comprises from about  $4 \times 10^8$  bacterial cells per mL of culture volume to about  $1 \times 10^9$  bacterial cells per  
25 mL in a volume of at least about 1 L (*e.g.*, from about 1 L to about 500,000 L, from about 1 L to about 10,000 L, from about 1 L to about 1,000 L, from about about 1 L to about 500 L, or from about 1 L to about 250 L).

In some embodiments, the cell culture comprises at least one exogenous antibiotic inhibitor of bacterial cell peptidoglycan biogenesis. In some embodiments, the cell culture comprises at least two  
30 structurally distinct exogenous antibiotic inhibitors of bacterial cell peptidoglycan biogenesis. In some cases, the at least two structurally distinct exogenous antibiotic inhibitors of bacterial cell peptidoglycan biogenesis inhibit different components of a peptidoglycan biogenesis pathway in the bacterial cell (*e.g.*, the at least two structurally distinct exogenous antibiotic inhibitors inhibit different enzymes of the peptidoglycan biogenesis pathway in the bacterial cell). In some cases, the cell culture comprises an

exogenous antibiotic inhibitor of a transglycosylase component of bacterial cell peptidoglycan biogenesis. In some cases, the cell culture comprises an exogenous antibiotic inhibitor of a transpeptidase component of bacterial cell peptidoglycan biogenesis. In some cases, the cell culture comprises an exogenous antibiotic inhibitor of UDP-N-acetylmuramyl (UDP-MurNAc)-pentapeptide biogenesis or UDP-N-acetylglucosamine (UDP-GlcNAc) biogenesis.

In some cases, the cell culture comprises an exogenous antibiotic inhibitor of MurA, MurB, MurC, MurD, MurE, MurF, MraY, MurG, FemX, FemA, FemB, FtsW, or a penicillin binding protein (PBP). In some cases, the cell culture comprises at least two structurally distinct exogenous antibiotic inhibitors, wherein the at least two structurally distinct exogenous antibiotic inhibitors inhibit different proteins selected from MurA, MurB, MurC, MurD, MurE, MurF, MraY, MurG, FemX, FemA, FemB, FtsW, or a penicillin binding protein (PBP). In some embodiments, the cell culture comprises at least one or at least two structurally distinct antibiotic(s) selected from:  $\beta$ -lactam antibiotics, phosphonic acid antibiotics, polypeptide antibiotics, D-cycloserine, and glycopeptide antibiotics, wherein the antibiotic(s) inhibit peptidoglycan biogenesis in the bacterial cell.

In some embodiments, the culture medium comprises at least one reactive oxygen species (ROS) scavenger (*e.g.*, reduced glutathione (GSH), or a thiol containing non-peptidic small molecule having a molecular weight from about 70 g/mol to about 350 g/mol, or from about 75 g/mol to about 155 g/mol).

In some embodiments, the culture medium comprises an antibiotic (*e.g.*, second or third antibiotic) that selects for the presence of a selectable marker in an expression vector that comprises an exogenous gene encoding for a protein of interest. In some embodiments, the antibiotic that selects for the presence of a selectable marker in the expression vector is not an inhibitor of peptidoglycan biogenesis in the bacterial cell.

In another aspect, methods of producing an exogenous protein of interest are provided (*e.g.*, using one or more of the foregoing cell cultures and/or bacterial cells), comprising: a) culturing a Gram-negative bacterial cell in a medium comprising a magnesium salt, wherein the concentration of magnesium ions in the culture medium is at least about 4, 5 or 6 mM, and wherein the bacterial cell comprises an exogenous gene encoding the protein of interest; b) inhibiting peptidoglycan biogenesis in the bacterial cell; and c) harvesting the protein from the medium. In further embodiments, the concentration of magnesium ions in the medium is at least about 7, 8, 9 or 10 mM. In some embodiments, the concentration of magnesium ions in the medium is between about 6 mM and about 20 mM. In some embodiments, the magnesium salt is selected from: magnesium sulfate and magnesium chloride. In some embodiments, the culturing of a), or a portion thereof and/or the inhibiting of b), or a portion thereof is performed in one or more of the foregoing cell cultures. In some embodiments, expression of the exogenous gene encoding the protein of interest is induced, *e.g.*, by adding an inducer to

the medium, during step b). In some embodiments, expression of the exogenous gene encoding the protein of interest is induced, *e.g.*, by adding an inducer to the medium, before step b). In some embodiments, expression of the exogenous gene encoding the protein of interest is induced, *e.g.*, by adding an inducer to the medium, after step b) has been initiated.

5 Preferably, the cell culture of the subject invention further comprises an osmotic stabilizer, including, *e.g.* sugars (*e.g.*, arabinose, glucose, sucrose, glycerol, sorbitol, mannitol, fructose, galactose, saccharose, maltotrioseerythritol, ribitol, pentaerythritol, arabitol, galactitol, xylitol, iditol, maltotriose, and the like), betaines (*e.g.*, trimethylglycine), proline, one or more salts such as an ammonium, potassium, or sodium salt (*e.g.*, sodium chloride), one or more polymers (*e.g.*, polyethylene glycol, polyethylene glycol monomethylether, polysucrose, polyvinylpyrrolidone, polypropylene glycol), or a  
10 combination thereof. In some cases, the concentration of the osmotic stabilizer(s) in the medium is at least about 4%, 5%, 6%, or 7% (w/v). In further embodiments, the concentration of osmotic stabilizer is at least about 8%, 9%, or 10% (w/v). In some embodiments, the concentration of the osmotic stabilizer in the medium is between about 5% to about 20% (w/v).

15 In some embodiments, the cell culture may further comprise ammonium chloride, ammonium sulfate, calcium chloride, amino acids, iron(II) sulfate, magnesium sulfate, peptone, potassium phosphate, sodium chloride, sodium phosphate, and yeast extract.

The bacterial cell may be cultured continuously or discontinuously; in a batch process, a fed-batch process or a repeated fed-batch process. In some embodiments, steps b) and c) occur sequentially.  
20 In other embodiments, steps b) and c) occur simultaneously. In some embodiments, step c) is performed at least 1 hour after step b).

In some embodiments, the inhibiting peptidoglycan biogenesis in the bacterial cell is performed by adding an antibiotic to the medium. In some cases, the inhibiting peptidoglycan biogenesis in the bacterial cell is performed by adding two or more structurally distinct antibiotics to the medium. In some  
25 cases, the antibiotic or antibiotics are selected from:  $\beta$ -lactam antibiotics (*e.g.* penicillins, cephalosporins, carbapenems, and monobactams), phosphonic acid antibiotics, polypeptide antibiotics, and glycopeptide antibiotics. In particular embodiments, the antibiotic or antibiotics are selected from alafosfalin, amoxicillin, ampicillin, aztreonam, bacitracin, carbenicillin, cefamandole, cefotaxime, cefsulodin, cephalothin, fosmidomycin, methicillin, nafcillin, oxacillin, penicillin g, penicillin v, fosfomycin,  
30 primaxin, D-cycloserine, and vancomycin. In some embodiments, the antibiotic or antibiotics are selected from inhibitors of MurA, MurB, MurC, MurD, MurE, MurF, MraY, MurG, FemX, FemA, FemB, FtsW, or a penicillin binding protein (PBP). In some embodiments, the inhibiting peptidoglycan biogenesis in the bacterial cell is performed by adding an inhibitor of MurA and an inhibitor of a penicillin binding protein (PBP) to the medium. In some embodiments, the inhibiting peptidoglycan

biogenesis in the bacterial cell is performed by adding an inhibitor of MurA to the medium. In some embodiments, the inhibiting peptidoglycan biogenesis in the bacterial cell is performed by adding an inhibitor of PBP to the medium.

5 Preferably, the modified bacterial cells of the subject invention are derived from Gram-negative bacteria, *e.g.* selected from: *gammaproteobacteria* and *alphaproteobacteria*. In particularly preferred embodiments, the bacterium is selected from: *Escherichia coli*, *Vibrio natriegens*, *Pseudomonas fluorescens*, *Caulobacter crescentus*, *Agrobacterium tumefaciens*, and *Brevundimonas diminuta*. In specific embodiments, the bacterium is *Escherichia coli*, *e.g.* strain BL21(DE3).

10 In one embodiment, the exogenous gene is integrated into the host bacterial cell genome. In another embodiment, the bacterial cell comprises an expression vector comprising the exogenous gene. In some embodiments, the medium comprises an antibiotic that selects for the presence of the expression vector. In some embodiments, the antibiotic that selects for the presence of the expression vector is not an inhibitor of peptidoglycan biogenesis in the bacterial cell. In an exemplary embodiment, the expression vector comprises a pET plasmid. In a particular embodiment, the expression vector comprises  
15 plasmid pET28a.

In a further embodiment, the subject methods comprise inducing expression of the exogenous gene. In some embodiments, expression of the exogenous gene is inducible by an inducer selected from, *e.g.* isopropyl- $\beta$ -d-l-thiogalactopyranoside, lactose, arabinose, maltose, tetracycline, anhydrotetracycline, vavlycin, xylose, copper, zinc, and the like.

20 In one embodiment, the modified bacterial cells further comprise a nucleic acid sequence encoding a signal peptide operably linked to the exogenous gene, wherein the signal peptide directs cotranslational export of the protein from the cytoplasm to the periplasm. In some embodiments, the signal peptide is derived from the Sec and Tat secretion pathways. In particular embodiments, the signal peptide is derived from DsbA, pelB, OmpA, TolB, MalE, lpp, TorA, or HylA.

25 In some embodiments, the culture medium has an OD<sub>600</sub> between about 0.1 to about 500; between about 0.2 to about 100, between about 0.5 to about 10, between about 1 to about 2. In exemplary embodiments, the medium has an OD<sub>600</sub> of about 1.1.

30 Expression of the exogenous gene may be induced for about 1 hour to about 1 week; for about 1 hour to about 1 day; for about 1 hour to about 10 hours; for about 10 hours to about 1 week; for about 10 hours to about 1 day; for about 1 day to about 1 week.

The yield of the protein of interest may be about 0.1 g/L medium to about 500 g/L medium; about 1 g/L medium to about 500 g/L medium; about 1 g/L medium to about 100 g/L medium; about 1 g/L medium to about 10 g/L medium; about 10 g/L medium to about 500 g/L medium; about 10 g/L medium to about 100 g/L medium; about 100 g/L medium to about 500 g/L medium. The yield of the protein of

interest may be about 10 mg/L medium to about  $10^3$  mg/L medium; about 20 mg/L medium to about 500 mg/L medium; about 100 mg/L medium to about 250 mg/L medium; or about 1 mg/L medium to about 10 mg/L medium. The yield of the protein of interest may be increased by at least about 2-fold, 3-fold, 5-fold, 8-fold, 10-fold, as compared to a method of making the protein of interest from genetically identical cells in an unswitched state. The yield of the protein of interest may be increased by from about 2-fold to about 100-fold, from about 2-fold to about 50-fold, from about 5-fold to about 25-fold, or from about 10-fold to about 20-fold. The yield of the protein of interest may be increased by from about 2-fold to about 10-fold, from about 2-fold to about 20-fold, or from about 2-fold to about 30-fold, as compared to a method of making the protein of interest from genetically identical cells in an unswitched state.

In some embodiments, the increased protein yields are increased as compared to methods of making a protein of interest from genetically identical cells under conditions that do not induce a switched L-form (e.g., wherein said conditions that do not induce a switched form are otherwise identical to conditions that provide increased protein of interest). In some cases, the conditions that do not induce a switched L-form comprise the absence of, or an insufficient amount of, one or more antibiotics that inhibit peptidoglycan biogenesis in the cell. In some cases, the conditions that do not induce a switched form additionally or alternatively comprise a magnesium concentration of less than 6 mM, less than 5 mM, less than 4 mM, less than 3 mM, less than 2 mM, or about 1 mM. In some cases, the conditions that do not induce a switched form additionally or alternatively comprise conditions in which the bacterial cell comprises a periplasmic space that is about 5% to about 30% or about 10% to about 20% of total cell volume.

In another aspect, the present invention provides a fermentation vessel containing any one of the foregoing cell cultures, wherein the cell culture contained by the fermentation vessel comprises a volume of medium of about, or of at least about, 1 L; 10 L; 100 L; 250 L; 500 L; or 1,000 L. In some cases, the fermentation vessel is a component of a fermentation system. In some cases, the fermentation system further comprises modules for controlling oxygen, carbon, or pH, or a combination of 2 or 3 thereof.

### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts the physiological state difference between switched and unswitched cells. A) Unswitched *Escherichia coli* cells. B) Same *Escherichia coli* population as figure A but has undergone the physiological switch. C) Phase contrast of switched *Escherichia coli* cell containing cytoplasmic RFP and periplasmic GFP. D) Fluorescent imaging of cell in figure C illustrates targeted protein localization.

Fig. 2 depicts enhanced protein production in switched cells. A-B) Target protein for T7 inducible protein production is periplasmic expressed GFP, produced in *Escherichia coli* BL21. The same population of cells was used and induced at OD 1.1. A) Protein ladder (lane 1), IPTG induced protein

production (lane 2), IPTG induced protein production with physiological switch (lane 3). B) Two vials of the cell GFP induced cultures with IPTG only on left and IPTG+ Switch on right. C) Expression of a 22KD collagen using switched cells showing protein ladder (lane 1), supernatant after protein production (lane 2), cell pellet (lane 3).

5 Fig. 3 depicts a timelapse of Escherichia coli cell switching over time.

Fig. 4 illustrates other organisms undergoing the physiological switch. A) *Agrobacterium tumefaciens* normal physiology. B) *Agrobacterium tumefaciens* switched physiology. C) *Pseudomonas aeruginosa* PAO1 normal physiology. D) *Pseudomonas aeruginosa* PAO1 switched physiology. E) *Brevundimonas diminuta* normal physiology. F) *Brevundimonas diminuta* switched physiology. G) *Agrobacterium tumefaciens* normal physiology. H) *Agrobacterium tumefaciens* switched physiology.

### DETAILED DESCRIPTION

In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the disclosure. However, one skilled in the art will understand that the disclosure may be practiced without these details.

Unless the context requires otherwise, throughout the present specification and claims, the word "comprise" and variations thereof, such as, "comprises" and "comprising" are to be construed in an open, inclusive sense, that is as "including, but not limited to".

Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

As used herein the term "about" refers to  $\pm 10\%$ .

The term "consisting of" means "including and limited to".

The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

Throughout this application, various embodiments of this disclosure may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 *etc.*, as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

### **L-form Bacteria**

The present invention provides a protein production platform comprising modified bacterial cells exhibiting a novel physiological switch phenotype (L-form) which inhibits cell division and promotes the growth of the periplasmic space in comparison to the cytoplasmic space. Recombinant protein production in these cells is dramatically increased compared to that in non-switched cells. This has been tested in several species of Gram negative bacteria (*Gammaproteobacteria: Escherichia coli, Vibrio natriegens, and Pseudomonas fluorescens;* and *Alphaproteobacteria: Caulobacter crescentus, Agrobacterium tumefaciens, and Brevundimonas diminuta*), which suggest a conserved mechanism that can be applied to all gram-negative recombinant protein production. These cells still contain an inner and outer membrane but lack a functional peptidoglycan cell wall. The cell shape is spherical and increases in volume over time. While the periplasmic space normally comprises only 10-20% of the total cell volume, the periplasmic compartment of the switched state of the subject invention can comprise up to 90% of total cell volume. Remarkably, and unexpectedly, the cells remain viable and are able to undergo metabolic processes and produce recombinant proteins of interest.

The term "recombinant bacterial cell" as used herein refers to a cell that has been engineered to express a target protein.

The term "coccus" as used herein refers to a bacterial cell having a spherical morphology. Generally the longest dimension of a coccus form bacterial cell is no more than 25%, 40%, 50%, or 100% larger than the shortest dimension.

The term "bacillus" as used herein refers to a bacterial cell having a rod-shaped morphology. Typically the longest dimension of a bacillus form bacterial cell is greater than twice the length of the shortest dimension. As such, the longest dimension of a bacillus form bacterial cell can be at least 3, 4, 5, 6, 7, 8, 9, or 10 times the length of the shortest dimension.

The term "periplasmic volume" refers to the total volume contained in the periplasm, which is the region between the outer membrane and the plasma membrane of the bacterial cell.

The term "cytoplasmic volume" refers to the total volume contained in the cytoplasm, which is the region inside the plasma membrane of the bacterial cell.

### Target Proteins

The present invention provides a platform of recombinant bacterial cells comprising exogenous genes for producing a protein of interest or "target protein" which is heterologous to the host. A protein or nucleic acid (e.g., nucleic acid encoding a protein, expression cassette, or expression vector) is heterologous to the host if it is not naturally occurring in the host, or is present in the host in a non-naturally occurring context (e.g., a non-natural genomic location or a non-natural subcellular location). For example, a naturally occurring gene can be operably linked to a promoter that is not operably linked to the naturally occurring gene in a corresponding wild-type organism, thereby forming a heterologous expression cassette in a modified bacterial cell. As another example, a naturally occurring genomic fragment that does not naturally exist in a plasmid in a wild-type bacterium can be subcloned into a plasmid and transformed into that bacterium, thereby forming a heterologous plasmid in a modified bacterial cell. The term "exogenous gene" refers to a gene that is introduced into the host organism by gene transfer. In some embodiments, exogenous genes encoding the target proteins of the invention are incorporated into expression vectors, which can be extrachromosomal or designed to integrate into the genome of the host cell into which it is introduced. Expression of the exogenous genes may be constitutive or inducible.

In some embodiments, the exogenous gene (e.g., cDNA or genomic DNA) used to produce the recombinant protein of interest, is suitably inserted into a replicable vector for expression in the bacterium under the control of a suitable promoter for bacteria. Many vectors are available for this purpose, and selection of the appropriate vector will depend mainly on the size of the nucleic acid to be inserted into the vector and the particular host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the particular

host cell with which it is compatible. Expression vectors can contain any number of appropriate regulatory sequences (including, but not limited to, transcriptional and translational control sequences, promoters, ribosomal binding sites, enhancers, origins of replication, *etc.*) or other components (selection genes, *etc.*), all of which are operably linked as is well known in the art.

5 Expression vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria.

10 Expression vectors also generally contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, *e.g.*, ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, *e.g.*, the gene encoding D-alanine racemase for *Bacilli*. One example of a selection scheme utilizes a drug to arrest growth of a host  
15 cell. Those cells that are successfully transformed with an exogenous gene produce a protein conferring drug resistance and thus survive the selection regimen. In one embodiment, the expression vector selection gene is not a gene that encodes for resistance to an inhibitor of peptidoglycan biogenesis in the bacterial cell.

20 The expression vector for producing a target protein may also contain an inducible promoter that is recognized by the host bacterial organism and is operably linked to the nucleic acid encoding the target protein. Inducible promoters suitable for use with bacterial hosts include the  $\beta$ -lactamase and lactose promoter systems (Chang *et al*, *Nature*, 275:615 (1978); Goeddel *et al*, *Nature*, 281:544 (1979)), the arabinose promoter system, including the araBAD promoter (Guzman *et al*, *J. Bacterid.*, 174: 7716-7728 (1992); Guzman *et al*, *J. Bacterid.*, 177:4121-4130 (1995); Siegele and Hu, *Proc. Natl. Acad. Sci. USA*,  
25 94:8168-8172 (1997)), the rhamnose promoter (Haldimann *et al*, *J. Bacterid.*, 180:1277-1286 (1998)), the alkaline phosphatase promoter, a tryptophan (*trp*) promoter system (Goeddel, *Nucleic Acids Res.*, 8:4057 (1980) and EP 36,776), the  $P_{L1\epsilon o-i}$  and  $P_{i_{c/ara-i}}$  promoters (Lutz and Bujard, *Nucleic Acids Res.*, 25:1203-1210 (1997)), and hybrid promoters such as the *tac* promoter. deBoer *et al*, *Proc. Natl. Acad. Sci. USA*,  
30 80:21-25 (1983). However, other known bacterial inducible promoters and low-basal-expression promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding the target protein.

Promoters for use in bacterial systems may also contain a Shine-Dalgarno (SD) sequence operably linked to the DNA encoding the target protein. The promoter can be removed from the bacterial source DNA by restriction enzyme digestion and inserted into the vector containing the desired DNA.

Construction of suitable vectors containing one or more of the above-listed components employs standard ligation techniques commonly known to those of skill in the art. Isolated plasmids or DNA fragments are cleaved, tailored, and re-ligated in the form desired to generate the plasmids required. Instructions for handling DNA, digestion and ligation of DNA, transformation and selection of transformants can be found *inter alia* in the known manual by Sambrook *et al.* "Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Laboratory Press, 1989).

The term "gene" as used herein refers to a nucleic acid fragment that expresses a specific protein, and which may refer to the coding region alone or may include regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence.

The term "expression vector" refers to an assembly which is capable of directing the expression of the exogenous gene. The expression vector may include a promoter which is operably linked to the exogenous gene.

The term "constitutive" as used herein refers to an exogenous gene that is expressed and not known to be subject to regulation that completely causes cessation of expression under most environmental and developmental conditions.

The term "inducible" as used herein refers to an exogenous gene that is expressed in response to presence of an inducer such as an exogenous chemical, heat, or light. Standard procedures may be followed to induce protein production in the L-form bacterial cells described herein. In some embodiments, the strain BL21(DE3) containing the plasmid pET28a may be used to drive the IPTG/lactose inducible production of recombinant proteins.

The term "target protein" as used herein refers generally to peptides and proteins having more than about 10 amino acids. The target proteins are preferably mammalian proteins. Target proteins generally exclude fluorescent proteins. In some embodiments the target protein is other than mCherry. In some embodiments the target protein is other than green fluorescent protein (GFP).

The term "therapeutic protein" as used herein refers to those proteins that have demonstrated biological activity and may be employed to treat a disease or disorder by delivery to a patient in need thereof by an acceptable route of administration. The biological activity of therapeutic proteins may be demonstrated *in vitro* or *in vivo* and results from interaction of the protein with receptors and/or other intracellular or extracellular components leading to a biological effect. Example of therapeutic proteins include, but are not limited to, molecules such as, *e.g.*, renin, a growth hormone, including human growth hormone; bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; a 1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; thrombopoietin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIc, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as

Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue -type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha; tumor necrosis factor-beta; enkephalinase; a serum albumin such as human serum albumin; mullerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse  
5 gonadotropin-associated peptide; a microbial protein, such as beta-lactamase; DNase; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; integrin; protein A or D; rheumatoid factors; a neurotrophic factor such as brain-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth factor such as NGF- $\beta$ ; cardiostrophins (cardiac hypertrophy factor) such as cardiostrophin-1 (CT-1); platelet-derived growth factor  
10 (PDGF); fibroblast growth factor such as aFGF and bFGF; epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-alpha and TGF-beta, including TGF- $\beta$ 1, TGF-p2, TGF-p3, TGF-p4, or TGF- $\beta$ 5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins; CD proteins such as CD-3, CD-4, CD-8, and CD-19; erythropoietin; osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon such as  
15 interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), *e.g.*, M-CSF, GM-CSF, and G-CSF; interleukins (ILs), *e.g.*, IL-1 to IL-13; anti-HER-2 antibody; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing receptors; addressins; and regulatory proteins.

In some embodiments the target protein is an antibody. Antibodies produced by the claimed  
20 invention may be monoclonal antibodies that are homogeneous populations of antibodies to a particular antigenic determinant (*e.g.*, a cancer cell antigen, a viral antigen, a microbial antigen, a protein, a peptide, a carbohydrate, a chemical, nucleic acid, or fragments thereof). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, and IgD and any subclass thereof.

Useful monoclonal antibodies include, but are not limited to, human monoclonal antibodies,  
25 humanized monoclonal antibodies, antibody fragments, or chimeric human-mouse (or other species) monoclonal antibodies.

The antibody can also be a bispecific antibody. Bispecific antibodies may have a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. This asymmetric  
30 structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation (WO 94/04690; Suresh *et al.* (1986) *Methods in Enzymology*, 121:210; Rodrigues *et al.* (1993) *J. of Immunology* 151:6954-6961; Carter *et al.* (1992)

Bio/Technology 10:163-167; Carter *et al.* (1995) *J. of Hematotherapy* 4:463-470; Merchant *et al.* (1998) *Nature Biotechnology* 16:677-681.

The antibody, as defined, can be a functionally active fragment, derivative or analog of an antibody that immunospecifically binds to cancer cell antigens, viral antigens, or microbial antigens or other antibodies bound to tumor cells or matrix. In this regard, "functionally active" means that the fragment, derivative or analog is able to elicit anti-anti-idiotypic antibodies that recognize the same antigen that the antibody from which the fragment, derivative or analog is derived recognized.

Specifically, in an exemplary embodiment the antigenicity of the idiotype of the immunoglobulin molecule can be enhanced by deletion of framework and CDR sequences that are C-terminal to the CDR sequence that specifically recognizes the antigen. To determine which CDR sequences bind the antigen, synthetic peptides containing the CDR sequences can be used in binding assays with the antigen by any binding assay method known in the art, *e.g.* the BIA core assay (Kabat *et al.* (1991) in *Sequences of Proteins of Immunological Interest*, Fifth Edition, National Institute of Health, Bethesda, Md.; Kabat *et al.* (1980) *J. of Immunology* 125(3):961-969).

Other useful antibodies include fragments of antibodies such as, but not limited to, F(ab')<sub>2</sub> fragments, which contain the variable region, the light chain constant region and the CHI domain of the heavy chain, can be produced by pepsin digestion of the antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Other useful antibodies are heavy chain and light chain dimers of antibodies, or any minimal fragment thereof such as Fvs or single chain antibodies (SCAs) (*e.g.*, as described in U.S. Pat. No. 4,946,778; Bird (1988) *Science* 242:423-42; Huston *et al.*, (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85:5879-5883; and Ward *et al.* (1989) *Nature* 334:544-54), or any other molecule with the same specificity as the antibody.

The antibody may be a fusion protein of an antibody, or a functionally active fragment thereof, for example in which the antibody is fused via a covalent bond (*e.g.*, a peptide bond), at either the N-terminus or the C-terminus to an amino acid sequence of another protein (or portion thereof, such as at least 10, 20 or 50 amino acid portion of the protein) that is not the antibody. The antibody or fragment thereof may be covalently linked to the other protein at the N-terminus of the constant domain.

The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison *et al.* (1984) *Proc. Natl. Acad. Sci. U.S.A.*, 81:6851-6855). A chimeric antibody is a molecule

in which different portions are derived from different animal species, such as those having a variable region derived from murine monoclonal and human immunoglobulin constant regions (U.S. Pat. Nos. 4,816,567; 4,816,397). Chimeric antibodies include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (*e.g.*, Old World Monkey, Ape *etc.*) and human constant region sequences.

Therapeutic monoclonal antibodies that may be produced by the bacteria and methods of the invention include, but are not limited to, trastuzumab (HERCEPTIN®, Genentech, Inc., Carter *et al.* (1992) Proc. Natl. Acad. Sci. U.S.A., 89:4285-4289; U.S. Pat. No. 5,725,856); anti-CD20 antibodies such as chimeric anti-CD20 "C2B8" (U.S. Pat. No. 5,736,137); rituximab (RITUXAN®), ocrelizumab, a chimeric or humanized variant of the 2H7 antibody (U.S. Pat. No. 5,721,108; WO 04/056312) or tositumomab (BEXXAR®); anti-IL-8 (St John *et al.* (1993) Chest, 103:932, and WO 95/23865); antibodies targeting other interleukins, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, and IL-13; anti-VEGF antibodies including humanized and/or affinity matured anti-VEGF antibodies such as the humanized anti-VEGF antibody huA4.6.1 bevacizumab (AVASTIN®, Genentech, Inc., Kim *et al.* (1992) Growth Factors 7:53-64; WO 96/30046; WO 98/45331); anti-PSCA antibodies (WO 01/40309); anti-CD40 antibodies, including S2C6 and humanized variants thereof (WO 00/75348); anti-CD11a (U.S. Pat. No. 5,622,700; WO 98/23761; Steppe *et al.* (1991) Transplant Intl. 4:3-7; Hourmant *et al.* (1994) Transplantation 58:377-380); anti-IgE (Presta *et al.* (1993) J. Immunol. 151:2623-2632; WO 95/19181); anti-CD18 (U.S. Pat. No. 5,622,700; WO 97/26912); anti-IgE, including E25, E26, and E27 (U.S. Pat. Nos. 5,714,338 and 5,091,313; WO 93/04173; U.S. Pat. No. 5,714,338); anti-Apo-2 receptor antibody (WO 98/51793); anti-TNF-alpha antibodies including cA2 (REMICADE®), CDP571, and MAK-195 (U.S. Pat. No. 5,672,347; Lorenz *et al.* (1996) J. Immunol. 156(4): 1646-1653; Dhainaut *et al.* (1995) Crit. Care Med. 23(9): 1461-1469); anti-Tissue Factor (TF) (EP 0 420 937 B1); anti-human alpha-4 beta 7 integrin (WO 98/06248); anti-EGFR, chimerized or humanized 225 antibody (WO 96/40210); anti-CD3 antibodies such as OKT3 (U.S. Pat. No. 4,515,893); anti-CD25 or anti-tac antibodies such as CHI-621 SIMULECT® and ZENAPAX® (U.S. Pat. No. 5,693,762); anti-CD4 antibodies such as the cM-7412 antibody (Choy *et al.* (1996) Arthritis Rheum 39(1):52-56); anti-CD52 antibodies such as CAMPATH-1H (Riechmann *et al.* (1988) Nature 332: 323-337); anti-Fc receptor antibodies such as the M22 antibody directed against Fc gamma RI as in Graziano *et al.* (1995) J. Immunol. 155(10):4996-5002; anti-carcinoembryonic antigen (CEA) antibodies such as hMN-14 (Sharkey *et al.* (1995) Cancer Res. 55(23 Suppl): 5935s-5945s; antibodies directed against breast epithelial cells including huBrE-3, hu-Mc 3 and CHL6 (Ceriani *et al.* (1995) Cancer Res. 55(23):5852s-5856s; and Richman *et al.* (1995) Cancer Res. 55(23 Suppl):5916s-5920s); antibodies that bind to colon carcinoma cells such as C242 (Litton *et al.* (1996) Eur J. Immunol. 26(1): 1-9); anti-CD38 antibodies, *e.g.*, AT 13/5 (Ellis *et al.* (1995) J. Immunol.

155(2):925-937); anti-CD33 antibodies such as Hu M195 (Jurcic *et al.* (1995) *Cancer Res* 55(23 Suppl):5908s-5910s) and CMA-676 or CDP771; anti-CD22 antibodies such as LL2 or LymphoCide (Juweid *et al.* (1995) *Cancer Res* 55(23 Suppl):5899s-5907s); anti-EpCAM antibodies such as 17- 1A (PANOREX®); anti-GpIIb/IIIa antibodies such as abciximab or c7E3 Fab (REOPRO®); anti-RSV  
5 antibodies such as MEDI-493 (SYNAGIS®); anti-CMV antibodies such as PROTOVIR®; anti-HIV antibodies such as PR0542; anti-hepatitis antibodies such as the anti-Hep B antibody OSTAVIR®; anti-CA 125 antibody OvaRex; anti-idiotypic GD3 epitope antibody BEC2; anti-human renal cell carcinoma antibody such as ch-G250; ING-1; anti-human 17- 1A antibody (3622W94); anti-human colorectal tumor antibody (A33); anti-human melanoma antibody R24 directed against GD3 ganglioside; anti-human  
10 squamous-cell carcinoma (SF-25); and anti-human leukocyte antigen (HLA) antibodies such as Smart ID 10 and the anti-HLA DR antibody Oncolym (Lym-1).

In some embodiments the target protein is non-therapeutic protein. Non-therapeutic proteins include, but are not limited to collagen and derivatives thereof, albumin, ovalbumin, rennet, fibrin, casein (including  $\alpha$ S1,  $\alpha$ S2,  $\beta$ ,  $\kappa$ ), elastin, keratin, myosin, fibronectin, laminin, nidogen-1, vitronectin, silk  
15 fibroins, prolyl hydroxylases, lysyl hydroxylases, glycosyltransferases, heme proteins and any other structural proteins and enzymes of commercial and/or academic interest.

In some embodiments the target protein is collagen. The term "collagen" as used herein refers to the main protein of connective tissue that has a high tensile strength and that has been found in most multicellular organisms. Collagen is a major fibrous protein, and it is also the nonfibrillar protein in  
20 basement membranes. It contains an abundance of glycine, proline, hydroxyproline, and hydroxylysine. Currently, collagen types I-XIX have been identified and they differ by the amino acid structure of the alpha chain. The term "collagen" as used herein is understood as meaning all collagen types and any form of collagen, whether native nor not, atelocollagen, insoluble collagen, collagen fibers, soluble collagen, and acid-soluble collagen.

25

### **Growth Media**

Growth media suitable for culturing the L-form bacteria described herein comprise at least 4 mM magnesium, preferably greater than 4 mM, more preferably greater than 5 mM, and still more preferably greater than 6 mM magnesium concentration, which may be in the form of either magnesium sulfate  
30 ( $\text{MgSO}_4$ ), magnesium chloride ( $\text{MgCl}_2$ ), or other magnesium salts known in the art. The media may also contain an osmotic stabilizer such as sucrose, glucose, or a betaine. In some embodiments, the concentration of osmotic stabilizer should be at least about 3%, 4% or 5% weight/volume.

The term "osmotic stabilizer" as used herein refers to a component used to control the osmotic strength of the medium and reduce turgor pressure inside the bacterial cells. Osmotic stabilizers can

include, but are not limited to, e.g. sugars (e.g., arabinose, glucose, sucrose, glycerol, sorbitol, mannitol, fructose, galactose, saccharose, maltotrioseerythritol, ribitol, pentaerythritol, arabitol, galactitol, xylitol, iditol, maltotriose, and the like), betaines (e.g., trimethylglycine), proline, one or more salts such as an ammonium, potassium, or sodium salt (e.g., sodium chloride), one or more polymers (e.g., polyethylene glycol, polyethylene glycol monomethylether, polysucrose, polyvinylpyrrolidone, polypropylene glycol),  
5 or a combination thereof. In some cases, the concentration of the osmotic stabilizer(s) in the medium is at least about 4%, 5%, 6%, or 7% (w/v). In further embodiments, the concentration of osmotic stabilizer is at least about 8%, 9%, or 10% (w/v). In some embodiments, the concentration of the osmotic stabilizer in the medium is between about 5% to about 20% (w/v).

10 In some embodiments, the total concentration of osmotic stabilizer (e.g., one or more of the osmotic stabilizers described above) is sufficient to provide a culture medium having an osmolality equal to the osmolality of switch media 1, switch media 2, or bioreactor media MGZ12, described hereinbelow in Example 1. In some embodiments, the the total concentration of osmotic stabilizer (e.g., one or more of the osmotic stabilizers described above) is sufficient to provide a culture medium having an osmolality  
15 that is from about 50% lower to about 50% higher than the osmolality of switch media 1, switch media 2, or bioreactor media MGZ12, described hereinbelow in Example 1. In some embodiments, the the total concentration of osmotic stabilizer (e.g., one or more of the osmotic stabilizers described above) is sufficient to provide a culture medium having an osmolality that is from about 25% lower to about 25% higher, or from about 10% lower to about 10% higher than the osmolality of switch media 1, switch  
20 media 2, or bioreactor media MGZ12, described hereinbelow in Example 1.

The term "sugar" as used herein refers to reducing sugars (e.g., cellobiose, fructose, galactose, glucose, glyceraldehyde, lactose, maltose, and ribose), non-reducing sugars (e.g., melezitose, melibiose, raffinose, sorbose, sucralose, sucrose, trehalose, and verbascose), and sugar alcohols (e.g., amltitol, arabitol, dulcitol, erythritol, glycerol, glycol, iditol, isomalt, lactitol, mannitol, rebitol, sorbitol, threitol, and xylitol)  
25

The term "betaine" as used herein refers to fully N-methylated amino acids, including, but not limited to trimethylglycine.

Salts and other nutrients should be added to the media to supplement growth. Salts and media compositions that support the physiological switch physiology that have been tested are M63 salt media, M9 salt media, PYE media, and Luria-Bertani (LB) media. Any necessary supplements besides carbon, nitrogen, and inorganic phosphate sources may also be included at appropriate concentrations introduced alone or as a mixture with another supplement or medium such as a complex nitrogen source. In certain  
30 embodiments, the medium further comprises one or more ingredients selected from: ammonium chloride,

ammonium sulfate, calcium chloride, casamino acids, iron(II) sulfate, magnesium sulfate, peptone, potassium phosphate, sodium chloride, sodium phosphate, and yeast extract.

In some embodiments, the cell culture is free of animal-derived components. In some embodiments, the cell culture comprises a defined medium. In some embodiments, the cell culture is free  
5 of yeast extract.

In some embodiments, the cell culture comprises from about  $1 \times 10^8$  bacterial cells per mL of culture volume to about  $1 \times 10^{10}$  bacterial cells per mL in a volume of at least about 1 L (e.g., from about 1 L to about 500,000 L, from about 1 L to about 10,000 L, from about 1 L to about 1,000 L, from about about 1 L to about 500 L, or from about 1 L to about 250 L). In some embodiments, the cell culture  
10 comprises from about  $4 \times 10^8$  bacterial cells per mL of culture volume to about  $1 \times 10^9$  bacterial cells per mL in a volume of at least about 1 L (e.g., from about 1 L to about 500,000 L, from about 1 L to about 10,000 L, from about 1 L to about 1,000 L, from about about 1 L to about 500 L, or from about 1 L to about 250 L).

In certain embodiments, the medium also contains a selection agent, chosen based on the  
15 construction of the expression vector, to selectively permit growth of prokaryotic cells containing the expression vector. For example, kanamycin is added to media for growth of cells expressing a kanamycin resistant gene.

In some embodiments, the cell culture comprises at least one exogenous antibiotic inhibitor of bacterial cell peptidoglycan biogenesis. An exogenous antibiotic inhibitor is an antibiotic as is commonly  
20 understood in the art and includes antimicrobial agents naturally produced by microorganisms such as bacteria (including *Bacillus* species), actinomycetes (including *Streptomyces*) or fungi that inhibit growth of or destroy other microbes, or genetically-engineered thereof and isolated from such natural source. Substances of similar structure and mode of action can be synthesized chemically, or natural compounds can be modified to produce semi-synthetic antibiotics. Exemplary classes of antibiotics include, but are  
25 not limited to, (1)  $\beta$ -lactams, including the penicillins, cephalosporins monobactams, methicillin, and carbapenems; (2) aminoglycosides, e.g., gentamicin, kanamycin, neomycin, tobramycin, netilmycin, paromomycin, and amikacin; (3) tetracyclines, e.g., doxycycline, minocycline, oxytetracycline, tetracycline, and demeclocycline; (4) sulfonamides (e.g., mafenide, sulfacetamide, sulfadiazine and sulfasalazine) and trimethoprim; (5) quinolones, e.g., ciprofloxacin, norfloxacin, and ofloxacin; (6)  
30 glycopeptides (e.g., vancomycin, telavancin, teicoplanin); (7) macrolides, which include for example, erythromycin, azithromycin, and clarithromycin; (8) carbapenems (e.g., ertapenem, doripenem, meropenem, and imipenem); (9) cephalosporins (e.g., cefadroxil, cefepime, and ceftobiprole); (10) lincosamides (e.g., clindamycin, and lincomycin); (11) monobactams (e.g., aztreonam); (12) nitrofurans (e.g., furazolidone, and nitrofurantoin); (13) Penicillins (e.g., amoxicillin, and Penicillin G); (14)

polypeptides (e.g., bacitracin, colistin, and polymyxin B); and (15) other antibiotics, e.g., ansamycins, polymycins, carbacephem, chloramphenicol, lipopeptide, and drugs against mycobacteria (e.g., the ones causing diseases in mammals, including tuberculosis (*Mycobacterium tuberculosis*) and leprosy (*Mycobacterium leprae*), and any combinations thereof. An exogenous antibiotic inhibitor of bacterial cell peptidoglycan biogenesis can be used, present in, or added to a culture, in an amount or concentration effective to inhibit or block bacterial cell peptidoglycan biogenesis. An exogenous antibiotic inhibitor of bacterial cell peptidoglycan biogenesis can be used, present in, or added to a culture, in an amount effective to inhibit or block bacterial cell division. An exogenous antibiotic inhibitor of bacterial cell peptidoglycan biogenesis can be used, present in, or added to a culture, in an amount or concentration effective to kill a bacterial cell in a culture medium containing less than 6, 5, 4, 3, or about 1 mM magnesium and/or osmotic stabilizers. An exogenous antibiotic inhibitor of bacterial cell peptidoglycan biogenesis can be used, present in, or added to a culture, in an amount or concentration that is at or above a minimum inhibitory concentration of the antibiotic inhibitor in control medium that does not induce a switched form. An exogenous antibiotic inhibitor of bacterial cell peptidoglycan biogenesis can be used, present in, or added to a culture, in an amount or concentration that is effective to reduce colony formation of bacteria on a test plate (e.g., LB agar) by at least about 95% or 99% as compared to the absence of the exogenous antibiotic inhibitor in a control test plate.

In some embodiments, the cell culture comprises at least two structurally distinct exogenous antibiotic inhibitors of bacterial cell peptidoglycan biogenesis. In some cases, the at least two structurally distinct exogenous antibiotic inhibitors of bacterial cell peptidoglycan biogenesis inhibit different components of a peptidoglycan biogenesis pathway in the bacterial cell (e.g., the at least two structurally distinct exogenous antibiotic inhibitors inhibit different enzymes of the peptidoglycan biogenesis pathway in the bacterial cell). In some cases, the cell culture comprises an exogenous antibiotic inhibitor of a transglycosylase component of bacterial cell peptidoglycan biogenesis. In some cases, the cell culture comprises an exogenous antibiotic inhibitor of a transpeptidase component of bacterial cell peptidoglycan biogenesis. In some cases, the cell culture comprises an exogenous antibiotic inhibitor of UDP-N-acetylmuramyl (UDP-MurNAc)-pentapeptide biogenesis or UDP-N-acetylglucosamine (UDP-GlcNAc) biogenesis.

In some cases, the cell culture comprises an exogenous antibiotic inhibitor of MurA, MurB, MurC, MurD, MurE, MurF, MraY, MurG, FemX, FemA, FemB, FtsW, or a penicillin binding protein (PBP). In some cases, the cell culture comprises at least two structurally distinct exogenous antibiotic inhibitors, wherein the at least two structurally distinct exogenous antibiotic inhibitors inhibit different proteins selected from MurA, MurB, MurC, MurD, MurE, MurF, MraY, MurG, FemX, FemA, FemB, FtsW, or a penicillin binding protein (PBP). In some embodiments, the cell culture comprises at least one

or at least two structurally distinct antibiotic(s) selected from:  $\beta$ -lactam antibiotics, phosphonic acid antibiotics, polypeptide antibiotics, D-cycloserine, and glycopeptide antibiotics, wherein the antibiotic(s) inhibit peptidoglycan biogenesis in the bacterial cell.

In some embodiments, the culture medium comprises at least one reactive oxygen species (ROS) scavenger (e.g., reduced glutathione (GSH), or a thiol containing non-peptidic small molecule having a molecular weight from about 70 g/mol to about 350 g/mol, or from about 75 g/mol to about 155 g/mol).

In some embodiments, the culture medium comprises an antibiotic (e.g., second or third antibiotic) that selects for the presence of a selectable marker in an expression vector that comprises an exogenous gene encoding for a protein of interest. In some embodiments, the antibiotic that selects for the presence of a selectable marker in the expression vector is not an inhibitor of peptidoglycan biogenesis in the bacterial cell.

### Physiological Switch

Without being bound by theory, the cell morphology that promotes recombinant protein production and inhibits cell division appears to be driven by the removal of the cell wall under the media conditions stated above. In some embodiments, the methods for removal/inhibition of cell wall synthesis can be through the use of antibiotics that inhibit peptidoglycan synthesis (such as ampicillin, carbenicillin, penicillins or fosfomycin), or other methods known in the art.

In some embodiments, the antibiotic is selected from:  $\beta$ -lactam antibiotics, phosphonic acid antibiotics, polypeptide antibiotics, and glycopeptide antibiotics. In some embodiments, the antibiotic is an antibiotic selected from: penicillins, cephalosporins, carbapenems, and monobactams. In some embodiments, the antibiotic is selected from: alafosfalin, amoxicillin, ampicillin, aztreonam, bacitracin, carbenicillin, cefamandole, cefotaxime, cefsulodin, cephalothin, fosmidomycin, methicillin, nafcillin, oxacillin, penicillin g, penicillin v, fosfomycin, primaxin, D-cycloserine, and vancomycin.

### Periplasmic Targeting

When having an appropriate signal sequence, recombinantly produced polypeptides can be secreted into the periplasmic space of bacterial cells. Joly, J.C. and Laird, M.W., in *The Periplasm* ed. Ehrmann, M., ASM Press, Washington D.C., (2007) 345-360. In the chemically oxidizing environment of the periplasm the formation of disulfide bonds and thereby the functionally correct folding of polypeptides is favored.

In general, the signal sequence may be a component of the expression vector, or it may be a part of the exogenous gene that is inserted into the vector. The signal sequence selected should be one that is recognized and processed (*i.e.*, cleaved by a signal peptidase) by the host cell. For bacterial host cells that

do not recognize and process the native signal sequence of the exogenous gene, the signal sequence is substituted by any commonly known bacterial signal sequence.

In some embodiments, recombinantly produced polypeptides can be targeted to the periplasmic space using the DsbA signal sequence. Dinh and Bernhardt, J Bacteriol, Sept. 20 11, 4984-4987. In  
5 some embodiments, recombinantly produced polypeptides can be targeted to the periplasmic space using an DsbA, pelB, OmpA, TolB, MalE, lpp, TorA, or HylA signal sequence. In some embodiments, recombinantly produced polypeptides can be targeted to the periplasmic space using a portion (at least 10%, 25%, 50%, 75%, 95%, 99%) of a gene encoding a protein that is secreted into the periplasmic space. For example, in some embodiments, recombinantly produced polypeptides can be targeted to the  
10 periplasmic space using a portion (at least 10%, 25%, 50%, 75%, 95%, 99%) of a gene encoding a protein DsbA, pelB, OmpA, TolB, MalE, lpp, TorA, or HylA, wherein the portion contains the signal sequence of DsbA, pelB, OmpA, TolB, MalE, lpp, TorA, or HylA respectively. In some embodiments, a recombinantly produced polypeptide can be targeted to the periplasmic space by fusing the gene encoding the polypeptide to a nucleic acid encoding all or substantially all of a protein that is secreted into the  
15 periplasmic space, e.g., a protein selected from DsbA, pelB, OmpA, TolB, MalE, lpp, TorA, or HylA, thereby producing a fusion protein. Generally, such periplasmic targeting employs an N-terminal fusion in which the signal sequence or portion containing the signal sequence is N-terminal to the polypeptide of interest.

## 20 **Fermentative Protein Production**

The present invention furthermore provides a process for fermentative preparation of a protein, comprising the steps of:

- a) culturing a recombinant Gram-negative bacterial cell in a medium comprising a magnesium salt, wherein the concentration of magnesium ions in the medium is at least about 6 mM, and  
25 wherein the bacterial cell comprises an exogenous gene encoding the protein, provided that the protein is other than mCherry or green fluorescent protein;
- b) inhibiting peptidoglycan biogenesis in the bacterial cell (*e.g.*, by adding to the medium 1, 2, or more antibiotics that inhibit peptidoglycan biogenesis); and
- c) harvesting the protein from the medium.

30 The bacteria may be cultured continuously—as described, for example, in WO 05/02 1772—or discontinuously in a batch process (batch cultivation) or in a fed-batch or repeated fed-batch process for the purpose of producing the target protein. In some embodiments, protein production is conducted on a large-scale. Various large-scale fermentation procedures are available for production of recombinant proteins. Large-scale fermentations have at least 1,000 liters of capacity, preferably about 1,000 to

100,000 liters of capacity. These fermentors use agitator impellers to distribute oxygen and nutrients, especially glucose (the preferred carbon/energy source). Small-scale fermentation refers generally to fermentation in a fermentor that is no more than approximately 20 liters in volumetric capacity.

For accumulation of the target protein, the host cell is cultured under conditions sufficient for  
5 accumulation of the target protein. Such conditions include, *e.g.*, temperature, nutrient, and cell-density conditions that permit protein expression and accumulation by the cell. Moreover, such conditions are those under which the cell can perform basic cellular functions of transcription, translation, and passage of proteins from one cellular compartment to another for the secreted proteins, as are known to those skilled in the art.

10 The bacterial cells are cultured at suitable temperatures. For *E. coli* growth, for example, the typical temperature ranges from about 20 °C to about 39 °C. In one embodiment, the temperature is from about 25 °C to about 37 °C. In another embodiment, the temperature is at about 30 °C.

The pH of the culture medium may be any pH from about 5-9, depending mainly on the host organism. For *E. coli*, the pH is from about 6.8 to about 7.4, or about 7.0.

15 For induction, typically the cells are cultured until a certain optical density is achieved, *e.g.*, an **OD<sub>600</sub>** of about 1.1, at which point induction is initiated (*e.g.*, by addition of an inducer, by depletion of a repressor, suppressor, or medium component, *etc.*) to induce expression of the exogenous gene encoding the target protein.

20 After product accumulation, the cells can be vigorously stirred or mixed (*e.g.*, vortexed), and/or centrifuged in order to induce lysis and release of recombinant proteins. The majority of the proteins are typically found in the supernatant but any remaining membrane bound proteins can be released using detergents (*e.g.*, a non-ionic detergent such as triton X-100).

In a subsequent step, the target protein, as a soluble or insoluble product released from the cellular matrix, is recovered in a manner that minimizes co-recovery of cellular debris with the product.

25 The recovery may be done by any means, but in one embodiment, can comprise of histidine tag purification through a nickel column. See for example, Purification of Proteins Using Polyhistidine Affinity Tags, Methods Enzymology. 2000 ; 326: 245-254.

30 The target protein captured in the initial recovery step may then be further purified for example by chromatography. General chromatographic methods and their use are known to a person skilled in the art. See for example, Chromatography, 5th edition, Part A: Fundamentals and Techniques, Heftmann, E. (ed), Elsevier Science Publishing Company, New York, (1992); Advanced Chromatographic and Electromigration Methods in Biosciences, Deyl, Z. (ed.), Elsevier Science BV, Amsterdam, The Netherlands, (1998); Chromatography Today, Poole, C. F., and Poole, S. K., Elsevier Science Publishing Company, New York, (1991); Scopes, Protein Purification Principles and Practice (1982); Sambrook, J.,

*et al.* (ed), Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; or Current Protocols in Molecular Biology, Ausubel, F. M., *et al.* (eds), John Wiley & Sons, Inc., New York. The following procedures are exemplary of suitable purification procedures: fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; 5 reversed-phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; and gel filtration using, for example, SEPHADEX™ G-75.

The following examples are provided for purposes of illustration, not limitation.

10

## EXAMPLES

### Example 1: Construction of the Modified Bacteria.

#### Materials and methods:

#### Strains:

#### Tested physiological switch and protein production:

15

*E. coli* BL2 1(DE3)- From NEB, product #c2527

*E. coli* K12 NCM3722- From The Coli Genetic Stock Center, CGSC# 12355

#### Tested physiological switch:

Gamma proteobacteria:

20

*Vibrio natriegens* - From ATCC, product #14048

*Pseudomonas fluorescens* - From ATCC, product # 3 1948

*Pseudomonas aeruginosa* PAOI- From ATCC, product # BAA-47

Alphaproteobacteria:

25

*Caulobacter crescentus* - From ATCC, product #19089

*Agrobacterium tumefaciens/Rhizobium radiobacter* - From ATCC, product #33970

*Brevundimonas diminuta* - From ATCC, product #13 184

#### Media compositions:

30

#### 1 liter 5x m63 salts:

10 g (NH<sub>4</sub>)<sub>2</sub>S<sub>04</sub> - From P212121, product #7783-20-2

68 g KH<sub>2</sub>P<sub>04</sub> - From P212121, product #7778-77-0

2.5 mg FeS<sub>04</sub>.7H<sub>2</sub>O - From Sigma Aldrich, product #F7002

Bring volume up to 1 liter with milliQ water

Adjust to pH 7 with KOH (From P212121, product #1310-58-3)

Autoclave mixture

**1 liter of 1M MgSO<sub>4</sub>:**

5 246.5 g MgSO<sub>4</sub> 7H<sub>2</sub>O - From P212121, product #10034-99-8

Bring volume up to 1 liter with milliQ water

Autoclave mixture

**1 liter of switch media 1:**

10 133.4 mL 5Xm63 salts

10 mL 1M MgSO<sub>4</sub>

38.6 g Glucose - From P212121, product #50-99-7

66.6 g Sucrose - From P212121, product #57-50-1

8.33 g LB mix - From P212121, product #1b-miller

15 Bring volume up to 1 liter with milliQ water

Filter sterilize mixture through a 0.22 μM pore vacuum filter (From Sigma Aldrich, product #CLS430517)

**1 liter of switch media 2:**

20 133.4 mL 5Xm63 salts

10 mL 1M MgSO<sub>4</sub>

38.6 g Glucose - From P212121, product #50-99-7

66.6 g Sucrose - From P212121, product #57-50-1

10 g Yeast Extract - From FisherSci.com, product #J60287A1

25 Bring volume up to 1 liter with milliQ water

Filter sterilize mixture through a 0.22 μM pore vacuum filter (From Sigma Aldrich, product #CLS430517)

**For Bioreactor growth:**

30

5 liter of bioreactor media MGZ12:

1) Autoclave 1L of Glucose at concentration of 500g/L in DI water. From VWR, product #97061-170.

2) Autoclave 1L of Sucrose at concentration of 500g/L in DI water. From GeneseeSci.com, product #62-112.

3) Autoclave in 3946mL of DI water:

20 g (NH<sub>4</sub>)<sub>2</sub>HP0<sub>4</sub>. From VWR, product # 97061-932.

66.5 g KH<sub>2</sub>P0<sub>4</sub>. From VWR, product # 97062-348.

22.5 g H<sub>3</sub>C<sub>6</sub>H<sub>5</sub>O<sub>7</sub>. From VWR, product #BDH9228-2.5KG.

5 2.95 g MgS0<sub>4</sub>.7H<sub>2</sub>O. From VWR, product # 97062-134.

10 mL Trace Metals (Teknova), 1000x. From Teknova, product #T1001.

After autoclaving add 400 mL of (1) to (3), 65 mL of 10M NaOH (from VWR, product #97064-480) to (3), and 666 mL of(2) to (3).

10 A feed of 500g/L of glucose can be used during fermentation run as needed.

At induction add:

50mL of 1M MgS0<sub>4</sub>.7H<sub>2</sub>O to a 5 L bioreactor

1 to 10mM concentration of IPTG. From carbosynth.com, product # EI05931

15 Add Fosfomycin (50 µg/mL or higher) and Carbenicillin (100 µg/mL or higher).

### Physiological switch:

The physiological switch is optimally flipped at an OD 600 of 1 to 1.1 for *E. coli* for growth in shake flasks at volumes up to 1L. For the other species tested, cultures were grown in switch media and

20 subcultured once cultures reached maximal OD 600. In all cases the physiological switch is flipped

through the addition of 100-200ug/mL Carbenicillin (From P212121, product #4800-94-6) and 50-100ug/mL Fosfomycin (From P212121, product #26016-99-9). The majority of the population is in the

switched state within a few hours. To confirm that cells underwent a physiological switch, cells were

25 Prior automated filter wheels and stage, LED-CFP/YFP/mCherry and LED-DA/FI/TX filter sets

(Semrock), a Lumencor Sola II SE LED illumination system, and a Hamamatsu Flash 4.0 V2 CMOS camera.

### Image analysis of physiological switch:

30 Images were analyzed using ImageJ to measure dimensions. In the switched state, the spherical outline of the outer membrane is treated as a sphere to calculate total volume ( $V=(4/3)OT^3$ ). The cytoplasmic volume is calculated as an ellipsoid that exists within the sphere ( $V=(4/3)\pi*(\text{longest radius})*(\text{short radius})^2$ ). To calculate the periplasmic volume, the cytoplasmic volume is subtracted from the total volume of the cell.

**Protein Expression and quantification:**

*E. coli* BL21(DE3) (NEB product #c2527) containing pET28a (emd Millipore product #69864) and its derivatives carrying GFP or collagen derivatives were grown in a shaking incubator at 37°C overnight in switch media containing 50mg/mL kanamycin (p212121 product # 2251 180). Next day, subcultures are  
5 started with a 1:10 dilution of the overnight culture into fresh switch media containing 50mg/mL kanamycin. The culture is then physiologically switched and protein production is induced simultaneously at an OD 600 of 1 to 1.1 (Read on a Molecular Devices Spectramax M2 microplate reader). The physiologically switch and protein production are flipped through the addition of 100ug/mL Carbenicillin, 50ug/mL Fosfomycin, and 100ug/mL IPTG (p212121 product #367-93-1). Protein  
10 expression is continued in the switched state from between 8 hours to overnight at room temperature (approximately 22°C) on an orbital shaker. In order to quantify total protein levels, Quick Start™ Bradford Protein Assay was used on mixed portion of culture and standard curves are quantitated on a Molecular Devices Spectramax M2 microplate reader. In order to quantitate the relative intensity of target protein production relative to the rest of the protein population the mixed portion of the cultures were run  
15 on Mini-PROTEAN® TGX™ Gels and stained with Bio-Safe™ Coomassie Stain.

Induction of protein production :

Standard procedures have been followed to induce protein production in the physiological state.  
20 We have been using the strain BL2 1(DE3) containing the plasmid pET28a driving the IPTG/lactose inducible production of recombinant proteins and targeting them to the periplasmic space using the DsbA signal sequence. Using the GFP protein, targeted to the periplasmic space as described above, we have demonstrated the ability to gain and increase of 5-fold in protein production when compared to un-switched cell populations induced at the same optical density, for the same amount of time (figures). The  
25 induction was optimal at an OD600 of 1.1 and induction was continued for 10 hours at which point the protein produced was measured at about 200 mg/mL.

\* \* \*

All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification are  
30 incorporated herein by reference, in their entirety to the extent not inconsistent with the present description.

From the foregoing it will be appreciated that, although specific embodiments described herein have been described herein for purposes of illustration, various modifications may be made without

deviating from the spirit and scope described herein. Accordingly, the disclosure is not limited except as by the appended claims.

## CLAIMS

What is claimed is:

1. A recombinant, Gram-negative, bacterial cell having a periplasm and a cytoplasm, wherein the ratio of the periplasmic volume to the cytoplasmic volume is between about 0.5: 1 and about 10:1, wherein the bacterial cell comprises an exogenous gene encoding a protein of interest.
2. The bacterial cell of claim 1, wherein the bacterium is selected from: *gammaproteobacteria* and *alphaproteobacteria*.
3. The bacterial cell of claim 2, wherein the bacterium is selected from: *Escherichia coli*, *Vibrio natriegens*, *Pseudomonas fluorescens*, *Caulobacter crescentus*, *Agrobacterium tumefaciens*, and *Brevundimonas diminuta*.
4. The bacterial cell of claim 3, wherein the bacterium is *Escherichia coli*.
5. The bacterial cell of claim 4, wherein the bacterium is *Escherichia coli* BL21(DE3).
6. The bacterial cell of any one of claims 1 to 5, wherein the ratio of the periplasmic volume to the cytoplasmic volume is between about 0.5: 1 and about 5:1.
7. The bacterial cell of any one of claims 1 to 5, wherein the ratio of the periplasmic volume to the cytoplasmic volume is between about 0.5: 1 and about 1:1.
8. The bacterial cell of any one of claims 1 to 5, wherein the ratio of the periplasmic volume to the cytoplasmic volume is between about 1:1 and about 10: 1.
9. The bacterial cell of any one of claims 1 to 5, wherein the ratio of the periplasmic volume to the cytoplasmic volume is between about 1:1 and about 5:1.
10. The bacterial cell of any one of claims 1 to 5, wherein the ratio of the periplasmic volume to the cytoplasmic volume is between about 5: 1 and about 10: 1.
11. The bacterial cell of any one of claims 1 to 10, wherein the bacterial cell is a coccus having a longest dimension of about 2  $\mu\text{m}$  to about 16  $\mu\text{m}$ .
12. The bacterial cell of claim 11, wherein the longest dimension is about 4  $\mu\text{m}$  to about 16  $\mu\text{m}$ .

13. The bacterial cell of claim 11, wherein the longest dimension is about 8  $\mu\text{m}$  to about 16  $\mu\text{m}$ .
14. The bacterial cell of claim 11, wherein the longest dimension is about 2  $\mu\text{m}$  to about 8  $\mu\text{m}$ .
15. The bacterial cell of claim 11, wherein the longest dimension is about 4  $\mu\text{m}$  to about 8  $\mu\text{m}$ .
16. The bacterial cell of claim 11, wherein the longest dimension is about 2  $\mu\text{m}$  to about 4  $\mu\text{m}$ .
17. The bacterial cell of any one of claims 1 to 16, wherein the bacterial cell comprises an expression vector comprising the exogenous gene.
18. The bacterial cell of claim 17, wherein the expression vector is free of a marker encoding for resistance to an inhibitor of bacterial cell peptidoglycan biogenesis.
19. The bacterial cell of claim 17 or 18, wherein the expression vector comprises a pET plasmid.
20. The bacterial cell of claim 19, wherein the expression vector comprises plasmid pET28a.
21. The bacterial cell of any one of claims 1 to 16, wherein the exogenous gene is integrated into a chromosome of the bacterial cell.
22. The bacterial cell of any one of claims 1 to 21, wherein the bacterial cell comprises a coccus form of an amp<sup>s</sup> and/or fosfomycin-sensitive bacillus strain, wherein the coccus form and the bacillus strain are genetically identical.
23. The bacterial cell of any one of claims 1 to 22, wherein expression of the exogenous gene is constitutive.
24. The bacterial cell of any one of claims 1 to 22, wherein expression of the exogenous gene is inducible.
25. The bacterial cell of claim 24, wherein the expression of the exogenous gene is inducible by an inducer selected from: isopropyl- $\beta$ -d-1-thiogalactopyranoside, lactose, copper, and zinc.
26. The bacterial cell of any one of claims 1 to 25, wherein the bacterial cell further comprises a nucleic acid sequence encoding a signal peptide operably linked to the exogenous gene, wherein the signal peptide directs cotranslational export of the protein from the cytoplasm to the periplasm.

27. The bacterial cell of claim 26, wherein the signal peptide is a periplasmic disulfide bond oxidoreductase.
28. The bacterial cell of claim 27, wherein the signal peptide is DsbA.
29. The bacterial cell of any one of claims 1 to 28, wherein the protein is collagen.
30. The bacterial cell of claim 29, wherein the collagen is human collagen.
31. The bacterial cell of claim 29, wherein the collagen is artificial collagen.
32. The bacterial cell of any one of claims 1 to 28, wherein the protein is a therapeutic protein.
33. The bacterial cell of claim 32, wherein the therapeutic protein is an antibody.
34. A cell culture comprising the bacterial cell of any one of claims 1 to 33 and a medium comprising a magnesium salt, wherein the concentration of magnesium ions in the medium is at least about 4 mM,
35. The cell culture of claim 34, wherein the concentration of magnesium ions in the medium is between about 4 mM and about 20 mM.
36. The cell culture of claim 34, wherein the concentration of magnesium ions in the medium is about 10 mM.
37. The cell culture of any one of claims 34 to 36, wherein the magnesium salt is selected from: magnesium sulfate and magnesium chloride.
38. The cell culture of any one of claims 34 to 37, wherein the medium further comprises an osmotic stabilizer.
39. The cell culture of claim 38, wherein the osmotic stabilizer is selected from: sugars and betaines.
40. The cell culture of any one of claims 34 to 39, wherein the concentration of the osmotic stabilizer in the medium is at least about 5%.
41. The cell culture of claim 40, wherein the concentration of the osmotic stabilizer in the medium is about 5% to about 20% (w/v).

42. The cell culture of claim 41, wherein the concentration of the osmotic stabilizer in the medium is about 10% (w/v).
43. The cell culture of any one of claims 34 to 42, wherein the medium further comprises one or more ingredients selected from: ammonium chloride, ammonium sulfate, calcium chloride, casamino acids, iron(II) sulfate, magnesium sulfate, peptone, potassium phosphate, sodium chloride, sodium phosphate, and yeast extract.
44. The cell culture of any one of claims 34 to 43, wherein the medium comprises from about  $1 \times 10^8$  bacterial cells per mL of culture volume to about  $1 \times 10^{10}$  bacterial cells per mL in a volume of at least about 1 L.
45. The cell culture of any one of claims 34 to 43, wherein the medium comprises from about  $4 \times 10^8$  bacterial cells per mL of culture volume to about  $1 \times 10^9$  bacterial cells per mL in a volume of at least about 1 L.
46. The cell culture of any one of claims 34 to 43, wherein the medium comprises from about  $4 \times 10^8$  bacterial cells per mL of culture volume to about  $1 \times 10^9$  bacterial cells per mL in a volume of at least about 1 L.
47. The cell culture of any one of claims 34 to 46, wherein the culture comprises at least one exogenous antibiotic inhibitor of bacterial cell peptidoglycan biogenesis.
48. The cell culture of claim 47, wherein the culture comprises at least two structurally distinct exogenous antibiotic inhibitors of bacterial cell peptidoglycan biogenesis.
49. The cell culture of claim 47, wherein the at least two structurally distinct exogenous antibiotic inhibitors of bacterial cell peptidoglycan biogenesis inhibit different components of a peptidoglycan biogenesis pathway in the bacterial cell.
50. The cell culture of any one of claims 34 to 49, wherein the culture medium comprises at least one reactive oxygen species (ROS) scavenger.
51. The cell culture of claim 50, wherein the ROS scavenger in the medium comprises reduced glutathione.
52. A method of producing a protein of interest comprising:

- a) culturing a recombinant Gram-negative bacterial cell in a medium comprising a magnesium salt, wherein the concentration of magnesium ions in the medium is at least about 6 mM, and wherein the bacterial cell comprises an exogenous gene encoding the protein;
  - b) inhibiting peptidoglycan biogenesis in the bacterial cell; and
  - c) harvesting the protein from the medium.
53. The method of claim 52, wherein steps b) and c) occur sequentially.
54. The method of claim 52, wherein step c) is performed at least 1 hour after step b).
55. The method of claim 52, wherein steps b) and c) occur simultaneously.
56. The method of claim 52, wherein the bacterial cell changes shape from bacillus to coccus after inhibiting peptidoglycan biogenesis in the bacterial cell.
57. The method of claim 52, wherein the inhibiting peptidoglycan biogenesis in the bacterial cell comprises adding an antibiotic to the medium, wherein the antibiotic inhibits peptidoglycan biogenesis in the bacterial cell.
58. The method of claim 57, wherein the inhibiting peptidoglycan biogenesis in the bacterial cell comprises adding at least two structurally distinct antibiotics to the medium, wherein the at least two structurally distinct antibiotics inhibit peptidoglycan biogenesis in the bacterial cell.
59. The method of claim 58, wherein the at least two structurally distinct antibiotics inhibit different components of a peptidoglycan biogenesis pathway in the bacterial cell.
60. The method of any one of claims 52 to 56, wherein the bacterium is selected from: *gammaproteobacteria* and *alphaproteobacteria*.
61. The method of claim 60, wherein the bacterium is selected from: *Escherichia coli*, *Vibrio natriegens*, *Pseudomonas fluorescens*, *Caulobacter crescentus*, *Agrobacterium tumefaciens*, and *Brevundimonas diminuta*.
62. The method of claim 60, wherein the bacterium is *Escherichia coli*.

63. The method of any one of claims 52 to 62, wherein the concentration of magnesium ions in the medium is between about 4 mM and about 20 mM.
64. The method of claim 63, wherein the concentration of magnesium ions in the medium is about 10 mM.
65. The method of any one of claims 52 to 64, wherein the magnesium salt is selected from: magnesium sulfate and magnesium chloride.
66. The method of any one of claims 52 to 65, wherein the medium further comprises an osmotic stabilizer.
67. The method of claim 66, wherein the osmotic stabilizer is selected from: sugars and betaines.
68. The method of claim 67, wherein the osmotic stabilizer is a sugar selected from: arabinose, glucose, and sucrose.
69. The method of claim 68, wherein the osmotic stabilizer is a betaine selected from: trimethylglycine .
70. The method of any one of claims 52 to 69, wherein the concentration of the osmotic stabilizer in the medium is at least about 5%.
71. The method of claim 70, wherein the concentration of the osmotic stabilizer in the medium is about 5% to about 20% (w/v).
72. The method of claim 70, wherein the concentration of the osmotic stabilizer in the medium is about 10% (w/v).
73. The method of any one of claims 52 to 72, wherein the medium further comprises one or more ingredients selected from: ammonium chloride, ammonium sulfate, calcium chloride, casamino acids, iron(II) sulfate, magnesium sulfate, peptone, potassium phosphate, sodium chloride, sodium phosphate, and yeast extract.
74. The method of any one of claims 52 to 73, wherein the medium comprises an antibiotic selected from:  $\beta$ -lactam antibiotics, phosphonic acid antibiotics, polypeptide antibiotics, and glycopeptide antibiotics, wherein the antibiotic inhibits peptidoglycan biogenesis in the bacterial cell.

75. The method of claim 74, wherein the antibiotic is a  $\beta$ -lactam antibiotic selected from: penicillins, cephalosporins, carbapenems, and monobactams.
76. The method of claim 74, wherein the antibiotic is selected from: alafosfalin, amoxicillin, ampicillin, aztreonam, bacitracin, carbenicillin, cefamandole, cefotaxime, cefsulodin, cephalothin, fosmidomycin, methicillin, nafcillin, oxacillin, penicillin g, penicillin v, fosfomycin, primaxin, and vancomycin.
77. The method of any one of claims 52 to 76, wherein the bacterial cell comprises an expression vector comprising the exogenous gene.
78. The method of claim 77, wherein the medium comprises an antibiotic that selects for the presence of the expression vector.
79. The method of claim 78, wherein the antibiotic that selects for the presence of the expression vector is not an inhibitor of a component of peptidoglycan biogenesis in the bacterial cell.
80. The method of claim 78, wherein the antibiotic that selects for the presence of the expression vector is an inhibitor of a component of protein synthesis or an inhibitor of FtsZ polymerization.
81. The method of claim 77, wherein the expression vector comprises a pET plasmid.
82. The method of any one of claims 42 to 76, wherein the exogenous gene is integrated into a chromosome of the bacterial cell.
83. The method of any one of claims 52 to 82, wherein the method further comprises inducing expression of the exogenous gene.
84. The method of claim 83, wherein the expression of the exogenous gene is inducible by an inducer selected from: isopropyl- $\beta$ -d-1-thiogalactopyranoside, lactose, copper, and zinc.
85. The method of any one of claims 52 to 84, wherein the bacterial cell further comprises a nucleic acid sequence encoding a signal peptide operably linked to the exogenous gene, wherein the signal peptide directs cotranslational export of the protein from the cytoplasm to the periplasm.
86. The method of claim 85, wherein the signal peptide is a periplasmic disulfide bond oxidoreductase.

87. The method of claim 86, wherein the signal peptide is DsbA.
88. The method of any one of claims 52 to 87, wherein the protein is collagen.
89. The method of claim 88, wherein the collagen is human collagen.
90. The method of any one of claims 52 to 87, wherein the protein is a therapeutic protein.
91. The method of claim 90, wherein the therapeutic protein is an antibody.
92. The method of any one of claims 52 to 91, wherein the medium has an  $OD_{600}$  of about 0.5 to about 5 after step b) and before step c).
93. The method of any one of claims 52 to 92, wherein step b) comprises inhibiting peptidoglycan biogenesis in the bacterial cell when the medium has an  $OD_{600}$  of from about 0.5 to about 2.
94. The method of any one of claims 52 to 93, wherein step c) comprises clarifying the medium by centrifugation, filtration, or a combination thereof.
95. The method of any one of claims 52 to 94, wherein step c) comprises extracting the protein from the periplasm by centrifugation, mixing or shaking, adding a non-ionic surfactant to the medium, or a combination thereof.
96. The method of any one of claims 52 to 96, wherein the yield of the protein is about 1 g/L medium to about 500 g/L medium
97. A recombinant Gram-negative bacterial cell prepared by steps a) and b) of the method of any one of claims 52 to 93.
98. A protein prepared by the method of any one of claims 52 to 96.
99. A fermentation vessel containing a cell culture of any one of claims 34 to 51, wherein the cell culture comprises a volume of medium of about, or of at least about, 1 L; 10 L; 100 L; 250 L; 500 L; or 1,000 L.

**Fig. 1**




Fig. 2




Fig. 3





Fig. 4



INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2017/024857

A. CLASSIFICATION OF SUBJECT MATTER  
INV. C12R1/19 C12N15/70  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
C12R C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal , WPI Data, BIOSIS, EMBL, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	D Scott Cayley ET AL: "Biophysical Characterization of Changes in Amounts and Activity of Escherichia Cell and Compartment Water and Turgor Pressure in Response to Osmotic Stress" , Biophysical Journal , 1 January 2000 (2000-01-01) , pages 1748-1764, XP055372826, UNITED STATES DOI : 10.1016/50006-3495 (00) 76726-9 Retrieved from the Internet: URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1300771/pdf/10733957.pdf [retrieved on 2017-05-16]	I - 4,6-9 , II- 18, 38-46, 97-99
Y	table 2 page 1750, column 1, lines 1-4 ----- -/- .	1-99



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

19 May 2017

Date of mailing of the international search report

31/05/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Obel , Nicolai

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2017/024857

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TEUTA PI LIZOTA ET AL: "Fast, Multi phase Volume Adaptation to Hyperosmotic Shock by Escherichia coli", PLOS ONE, vol . 7, no. 4, 13 April 2012 (2012-04-13) , page e35205 , XP055372863 , DOI: 10.1371/journal.pone.0035205	1-4,6-9 , 11-18, 38-46, 97-99
Y	page 2; figure 1 page 4; figure 3	1-99
X	----- EP 1 323 820 A2 (GENENTECH INC [US] ) 2 July 2003 (2003-07-02)	52-99
Y	paragraphs [0126] - [0127] ; claim 1; table 2	1-99
X	----- H. -D Gortz ET AL: "Changes in Fine Structure and Polypeptide Pattern during Development of Holospora obtusa, a Bacterium Infecting the Macronucleus of Paramecium caudatum", JOURNAL OF BACTERIOLOGY, vol . 172, no. 10 1 October 1990 (1990-10-01) , pages 5664-5669 , XP055373233 , Retrieved from the Internet: URL: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526880/pdf/jbacter00164-0156.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526880/pdf/jbacter00164-0156.pdf</a> [retrieved on 2017-05-16] page 5664, column 1, lines 23-24	1,2,6-9 , 97-99
X	----- HAWORTH R S ET AL: "Uncoupler resistance in E. coli Tuv and Cuv is due to the exclusion of uncoupler by the outer membrane", BIOCHIMICA ET BIOPHYSICA ACTA. BIOENERGETICS, AMSTERDAM, NL, vol . 1019, no. 1, 9 August 1990 (1990-08-09) , pages 67-72 , XP023349580, ISSN: 0005-2728, DOI : 10.1016/0005-2728(90)90125-N [retrieved on 1990-08-09] table 2	1-4,6,7
A	----- Wo 2016/004334 A1 (GENOMATICA INC [US] ) 7 January 2016 (2016-01-07) paragraph [00123] paragraph [00195]	1-99

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2017/024857
---------------------------------------------------

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1323820	A2	02-07-2003	
		AT 250125 T	15-10-2003
		AT 415469 T	15-12-2008
		AU 752429 B2	19-09-2002
		CA 2346797 A1	04-05-2000
		CY 1109847 T1	10-09-2014
		DE 69911450 D1	23-10-2003
		DE 69911450 T2	22-07-2004
		DK 1124941 T3	02-02-2004
		DK 1323820 T3	16-03-2009
		EP 1124941 A1	22-08-2001
		EP 1323820 A2	02-07-2003
		ES 2207340 T3	16-05-2004
		ES 2318070 T3	01-05-2009
		IL 142269 A	30-12-2010
		JP 3711326 B2	02-11-2005
		JP 2002528071 A	03-09-2002
		PT 1124941 E	27-02-2004
		PT 1323820 E	05-03-2009
		US 6180367 B1	30-01-2001
		US 6258560 B1	10-07-2001
		WO 0024873 A1	04-05-2000
WO 2016004334	AI	07-01-2016	
		EP 3164495 A1	10-05-2017
		WO 2016004334 A1	07-01-2016